Why Kala Pharmaceuticals Stock is Soaring

Kala Pharmaceuticals 
Kala Pharmaceuticals (KALA) announced today that the U.S. FDA has accepted the investigational new drug application (IND) for its lead product candidate, KPI-012, a human Mesenchymal Stem Cell Secretome (MSC-S) for the treatment of persistent corneal epithelial defect (PCED).

Kala is a . . .

This content is for paid subscribers.
Please click here to subscribe or here to log in.